Immunohistochemistry results were as follows: Adenocarcinoma component: CK8/18(+), CK7(+), Syn(-), EMA(+), Hepatocyte(-), Ki-67(40%+), Her2(1+), MLH1(+), PMS2(+), MSH2(+), MSH6(+), P53(80%+, mutated); Poorly differentiated carcinoma component: CK8/18(+), CK7(-), Syn(strong+), EMA(-), Hepatocyte(-), Ki-67(50%+), Her2(1+), MLH1(+), PMS2(+), MSH2(+), MSH6(+), P53(80%+, mutated); PD-L1(BP6099, TC score: 5%+). This evidence concerns the gene ERBB2 and adenocarcinoma.